Drug Profile
Research programme: food allergy immunotherapeutics - Aimmune Therapeutics/Nestle Health Science
Alternative Names: Food allergy OIT - Aimmune Therapeutics; Food allergy oral immunotherapies - Aimmune TherapeuticsLatest Information Update: 16 Oct 2020
Price :
$50
*
At a glance
- Originator Aimmune Therapeutics
- Class Allergens; Antiallergics; Food allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Food hypersensitivity
Most Recent Events
- 14 Oct 2020 Aimmune Therapeutics has been acquired by Nestle
- 28 Oct 2019 No recent reports of development identified for preclinical development in Food-hypersensitivity in USA (PO)
- 12 Mar 2018 Aimmune Therapeutics intends to file an IND application with the US FDA for AR 301 for food allergy (walnut allergy) in second half of 2019